Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SSGJ-709 · 1 trial · 1 indication
Dose limiting toxicity
TEAE is any untoward medical occurrence in a participant, temporally associated with the use of study treatment, whether or not considered related to the study treatment.
| Arm | Type | Description |
|---|---|---|
| Experimental: SSGJ-709 | EXPERIMENTAL | In dose escalation phase, SSGJ-709 will be conducted using accelerated titration and traditional 3+3 design. Dose Escalation Level includes 5 levels, Q3W IV. During or after dose escalation, any dose level that does not exceed the MTD can be expanded. |
| Name | Type | Description |
|---|---|---|
| SSGJ-709 | DRUG | A bispecific antibody targeting PD-1 and LAG-3. |
Inclusion Criteria: * Minimum life expectancy of 3 months; * Eastern Cooperative Oncology Group (ECOG) Performance status (PS) score of 0-1; * Locally advanced or metastatic malignant tumors confirmed by histopathology or cytology; preferred tumor types for enrollment include head and neck squamous...
SSGJ-709 is an investigational small molecule being developed for the treatment of advanced malignant tumors. It is currently being studied in a Phase 1 clinical trial in patients with advanced malignant tumors. The drug is not yet approved and remains in clinical development.
SSGJ-709 is a small molecule therapeutic being developed for oncology. The specific molecular target of SSGJ-709 has not been disclosed in the available information. The drug is currently in Phase 1 clinical development for advanced malignant tumors.
SSGJ-709 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol SBFM. The company is conducting a Phase 1 clinical trial of SSGJ-709 in patients with advanced malignant tumors.
SSGJ-709 is in Phase 1 clinical development. It is an investigational drug being studied in a Phase 1 trial for advanced malignant tumors. The drug is not FDA approved and is still in the early stages of clinical testing.
SSGJ-709 is being studied in a Phase 1 clinical trial with the identifier NCT07016490. This trial is titled 'A Phase 1 Study of SSGJ-709 in Patients With Advanced Malignant Tumors' and is currently recruiting participants in Australia. The study plans to enroll 15 patients.
SSGJ-709 is the primary name for this investigational drug being developed by Sunshine Biopharma Inc. No alternative names for SSGJ-709 have been disclosed in the available information. The drug is currently in Phase 1 clinical development for advanced malignant tumors.